Arovella Therapeutics (ASX:ALA) has announced that Dr Thomas Duthy is retiring effective 1 July as a non-executive director and chairman of the company to pursue new business opportunities.
Arovella is developing its invariant Natural Killer T (iNKT) cell therapy platform.
The company's CEO and managing director, Dr Michael Baker, said, “We thank Tom for his contributions to the Company since 2023. The Company is in a terrific position as it embarks on taking its lead CAR-iNKT cell therapy program into phase 1. Arovella will seek an experienced individual to chair the Company as we transition to clinical trials for our lead program ALA-101 and develop our solid tumour pipeline.”
Dr Elizabeth Stoner, one of Arovella’s current non-executive directors, will serve as interim chair while the company undertakes a thorough process to appoint a new chair. Dr Stoner has previously held the position of interim chair at Arovella.
Dr Duthy said, “It has been a privilege to serve as Chairman of Arovella. I'm proud of the progress the Company has made during my tenure, particularly in advancing its iNKT cell therapy platform towards the clinic with the benefit of a strong, deployable balance sheet and supportive shareholders. I wish the team every success into the future.”